| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d39573398ad3a0a5d94465e4356d024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_690599b7e00c5a0076d846def4395d28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b93d93c9c6b701bcdf12fd3ea690e47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82ce993b8e3f93031578cb446d1e9a6d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2202-064
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2205-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0083
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2250-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0066 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate |
2010-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6720ca704e4576141326f6c507342268
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98b375b3a17e3a5cf68e4bc0a16e4388
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3615e594eee96c93613472d9d70ca2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7982ce5554de9db6ee004597003c666 |
| publicationDate |
2011-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011171141-A1 |
| titleOfInvention |
Administration of dihydroergotamine mesylate particles using a metered dose inhaler |
| abstract |
Disclosed are compositions of matter and related methods that provide a metered dose inhaler that includes a formulation having a dose that comprises a hydrofluoroalkane propellant and dihydroergotamine mesylate particles; wherein the dose includes between 0.1 mg to 4 mg of dihydroergotamine mesylate; wherein the dihydroergotamine mesylate particles have a cumulative drug substance particle size distribution with d10>0.5 micron volumetric median diameter and d90<5.0 micron volumetric median diameter. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017261520-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9987443-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10758532-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020054558-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8945605-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021146318-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013163517-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014100359-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9408988-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115279371-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016531850-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10335558-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8778383-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020007342-A |
| priorityDate |
2009-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |